Clinical Trial Detail

NCT ID NCT03924245
Title Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers
Recruitment Recruiting
Gender female
Phase Phase Ib/II
Variant Requirements Yes
Sponsors Vanderbilt-Ingram Cancer Center
Indications

peritoneal carcinoma

ovarian carcinoma

fallopian tube carcinosarcoma

ovarian carcinosarcoma

fallopian tube carcinoma

Therapies

Entinostat

Entinostat + Olaparib

Age Groups: senior adult

Additional content available in CKB BOOST